Opdivo + Yervoy fails adjuvant phase 3 trial
Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy... Read More
We would like to invite you to be kept up to date with news from the
charity by signing up to our newsletter. Please enter you email address below.
*By submitting your email address you are agreeing to us contacting you with news and appeals from Kidney Cancer
UK & Scotland. We will never share any of your information with any third parties.